SynthesisEye (London, England)2024
Global estimates on the number of people blind or visually impaired by glaucoma: A meta-analysis from 2000 to 2020.
Synthesis in Eye (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.
- Beyond prevalence: diagnostic heterogeneity in population-based glaucoma studies in Africa-a systematic review.Frontiers in medicine · 2026Pooled it
- Efficacy and safety of sepetaprost in patients with primary open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J1 study.Japanese journal of ophthalmology · 2026Trial
- A Randomized Controlled Trial Comparing STREAMLINE Canaloplasty to Trabecular Micro-Bypass Stent Implantation in Primary Open-Angle Glaucoma.Clinical ophthalmology (Auckland, N.Z.) · 2024Trial
- Trends and disparities of vision impairment in Mexico from 1990 to 2023: a comparative analysis with Latin America and the Caribbean based on the Global Burden of Disease Study 2023.Lancet regional health. Americas · 2026Article
- Nanoformulations for Ocular Drug Delivery in Glaucoma: From Metal-Based Nanoparticles to Advanced Nanocarriers.Pharmaceutics · 2026Review
- Temporal changes in aqueous humor inflammatory cytokines of the contralateral eye after unilateral phacotrabeculectomy in rabbits.Scientific reports · 2026Article
- Global Ophthalmology Research Output Relative to Disease Burden and National Income, 2011-2021.Vision (Basel, Switzerland) · 2026Article
- Article
- Current burden and future projections of glaucoma in the United Kingdom.The British journal of ophthalmology · 2026Article
- Machine Learning-Based Prediction of Long-Term Intraocular Pressure Fluctuations in Open-Angle Glaucoma.Ophthalmology science · 2026Article
- Cross-linked actin networks (CLANs) and their role in the trabecular meshwork.Experimental eye research · 2026Review
- Clinic-based burden of glaucoma among Sahrawi refugees in the Tindouf camps.BMJ open ophthalmology · 2026Article
- Single-cell analysis reveals cellular heterogeneity and limits of marker-based assessment in retinal ganglion cell-enriched organoid cultures.Molecular medicine (Cambridge, Mass.) · 2026Article
- Predictive value of peripheral blood lymphocytes for glaucoma susceptibility: a clinical observational study.BMC ophthalmology · 2026Observational
- Effects of Ripasudil Hydrochloride Hydrate-Brimonidine Tartrate Fixed-Dose Combination Using Rho Kinase Inhibitor and Alpha2 Adrenergic Receptor Agonist on Aqueous Column in the Episcleral Vein: A Randomized, Double-Masked, Crossover Clinical Trial (ROCK Alpha-Aqua Study).Journal of clinical medicine · 2026Article
- Intraocular pressure induced blood retinal barrier compromise in mouse models and human glaucoma.Nature communications · 2026Article
- Vision-related quality of life after phacoemulsification combined with goniosynechialysis and goniotomy in patients with primary angle-closure glaucoma and cataract.BMC ophthalmology · 2026Article
- Peripheral Blood Mononuclear Cell Oxygen Consumption and Systemic Bioenergetics in Glaucoma Management.International journal of molecular sciences · 2026Review
- Optic Nerve Head Spatial Transcriptomic Change in Nonhuman Primate Early Experimental Glaucoma.Investigative ophthalmology & visual science · 2026Article
- The population characteristics and prevalence of visual impairment in a Southern European population.European journal of ophthalmology · 2026Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 20 institutions in 47 countries.
Funding
Abstract
objectivesTo estimate global and regional trends from 2000 to 2020 of the number of persons visually impaired by glaucoma and their proportion of the total number of vision-impaired individuals.
methodsA systematic review and meta-analysis of published population studies and grey literature from 2000 to 2020 was carried out to estimate global and regional trends in number of people with vision loss due to glaucoma. Moderate or severe vision loss (MSVI) was defined as visual acuity of 6/60 or better but <6/18 (moderate) and visual acuity of 3/60 or better but <6/60 (severe vision loss). Blindness was defined as presenting visual acuity <3/60.
resultsGlobally, in 2020, 3.61 million people were blind and nearly 4.14 million were visually impaired by glaucoma. Glaucoma accounted for 8.39% (95% uncertainty intervals [UIs]: 6.54, 10.29) of all blindness and 1.41% (95% UI: 1.10, 1.75) of all MSVI. Regionally, the highest proportion of blindness relating to glaucoma was found in high-income countries (26.12% [95% UI: 20.72, 32.09]), while the region with the highest age-standardized prevalence of glaucoma-related blindness and MSVI was Sub-Saharan Africa. Between 2000 and 2020, global age-standardized prevalence of glaucoma-related blindness among adults ≥50 years decreased by 26.06% among males (95% UI: 25.87, 26.24), and by 21.75% among females (95% UI: 21.54, 21.96), while MSVI due to glaucoma increased by 3.7% among males (95% UI: 3.42, 3.98), and by 7.3% in females (95% UI: 7.01, 7.59).
conclusionsWithin the last two decades, glaucoma has remained a major cause of blindness globally and regionally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.